SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Psychological concept. Chaotic thought process
Psychedelics
Cybin’s Small Depression Study Shows 71% Remission Rate
Phase II results for Cybin’s psilocin therapy showed remission rates of 71%, but just eight patients made it to the 12-month milestone.
November 18, 2024
 · 
2 min read
 · 
Annalee Armstrong
Fall of the Ukraine Economy. Recession graph with a red arrow on the Ukraine flag. Economic decline. Decline in the economy of stock trading. Downward trends in the economy. Business.
Gene therapy
Neurogene Details Gene Therapy Complication, Sending Shares Plummeting Again
Neurogene’s shares fell by 36% as the market opened Monday morning following news that a patient experienced systemic hyperinflammatory syndrome in a Phase I/II clinical trial of Rett syndrome gene therapy NGN-401.
November 18, 2024
 · 
2 min read
 · 
Annalee Armstrong
Chinese flag with digital matrix -Innovation Concept - Digital Tech Wallpaper - 3D illustration
Weight loss
Novo’s Wegovy Launched in China at a Fraction of US Price
Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine for about $193.27 for a one-month supply.
November 18, 2024
 · 
1 min read
 · 
Annalee Armstrong
Human liver protection. Wireframe low poly style. Concept for medical, pharmacology, treatment of the hepatitis. Abstract modern 3d vector illustration on dark blue background.
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
 · 
2 min read
 · 
Tristan Manalac
2D illustration showing scientists' hands editing a DNA strand
Gene editing
Intellia’s CRISPR Gene Editor Shows Early Promise With Strong Biomarker Benefit in ATTR Amyloidosis
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s Amvuttra.
November 18, 2024
 · 
3 min read
 · 
Tristan Manalac
Sino Biological SignalChem Tau Proteins
Sponsored
SignalChem’s Tau Proteins: Accelerating Neurodegenerative Disease Research
SignalChem Biotech provides diverse recombinant Tau proteins for research, helping advance tau-targeted therapies that may modify disease progression in Alzheimer’s and related tauopathies.
November 18, 2024
 · 
3 min read
Editable vector illustration of a man winning a race. Hi-res jpeg file included.
Editorial
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is ‘sole muscarinic winner.’
November 18, 2024
 · 
5 min read
 · 
Heather McKenzie
Contemporary art collage. Conceptual image. Businessman catching money given by a hand. In search of profit. Concept of business, economy, financial growth, promotion, following
Earnings
Bluebird Faces Cash Gap With Breakeven Point in Sight
Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a projected breakeven point before the end of 2025, with analysts worried they won’t make it.
November 15, 2024
 · 
4 min read
 · 
Annalee Armstrong
Recession arrow, Graph showing business decline on led screen
Drug Development
Eyenovia Shares Plummet 70% After It Drops Lead Program
Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination of its lead program in pediatric progressive myopia due to lack of efficacy.
November 15, 2024
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS